What is he best known for?
The fields of study he is best known for:
- Cancer
- Gene
- Internal medicine
Prostate cancer, Cancer research, Internal medicine, Oncology and Pathology are his primary areas of study.
The study incorporates disciplines such as Prostate and Antibody in addition to Prostate cancer.
His studies deal with areas such as Receptor, Bioinformatics, Circulating tumor cell and Somatic evolution in cancer as well as Cancer research.
Internal medicine is often connected to Endocrinology in his work.
The Oncology study combines topics in areas such as Abiraterone acetate, Clinical trial and Denosumab.
His Pathology research includes elements of Metastasis and Monoclonal Antibody J591.
His most cited work include:
- Renal-cell carcinoma. (1990 citations)
- Integrative clinical genomics of advanced prostate cancer (1675 citations)
- Divergent clonal evolution of castration-resistant neuroendocrine prostate cancer (662 citations)
What are the main themes of his work throughout his whole career to date?
David M. Nanus mainly focuses on Prostate cancer, Internal medicine, Oncology, Cancer research and Cancer.
David M. Nanus combines subjects such as Docetaxel, Prostate and Circulating tumor cell with his study of Prostate cancer.
His Endocrinology research extends to the thematically linked field of Internal medicine.
His research in Oncology intersects with topics in Gemcitabine, Clinical trial, Enzalutamide and Cohort.
His Cancer research study incorporates themes from Cell, Pathology, Antibody, Monoclonal antibody and Retinoic acid.
The various areas that he examines in his Cancer study include Immunology and PTEN.
He most often published in these fields:
- Prostate cancer (50.82%)
- Internal medicine (48.24%)
- Oncology (37.00%)
What were the highlights of his more recent work (between 2017-2021)?
- Prostate cancer (50.82%)
- Internal medicine (48.24%)
- Oncology (37.00%)
In recent papers he was focusing on the following fields of study:
His primary areas of study are Prostate cancer, Internal medicine, Oncology, Cancer research and Cancer.
His Prostate cancer research is multidisciplinary, relying on both Chemotherapy, Circulating tumor cell and Dose escalation.
His Oncology research is multidisciplinary, incorporating elements of Docetaxel, Enzalutamide, Radionuclide therapy and Cohort.
His Cancer research research is multidisciplinary, incorporating perspectives in Prostate, Glutamate carboxypeptidase II, Downregulation and upregulation, Antibody and Targeted radionuclide therapy.
His Prostate research includes themes of Biopsy and DNA methylation.
His study looks at the relationship between Cancer and topics such as Disease, which overlap with Diabetes mellitus.
Between 2017 and 2021, his most popular works were:
- Prospective Multicenter Validation of Androgen Receptor Splice Variant 7 and Hormone Therapy Resistance in High-Risk Castration-Resistant Prostate Cancer: The PROPHECY Study (122 citations)
- Patient derived organoids to model rare prostate cancer phenotypes (92 citations)
- A Phase II Trial of the Aurora Kinase A Inhibitor Alisertib for Patients with Castration-resistant and Neuroendocrine Prostate Cancer: Efficacy and Biomarkers (73 citations)
In his most recent research, the most cited papers focused on:
- Cancer
- Gene
- Internal medicine
His main research concerns Prostate cancer, Cancer research, Oncology, Internal medicine and Circulating tumor cell.
David M. Nanus specializes in Prostate cancer, namely Androgen receptor.
His research integrates issues of Dose escalation, Phenotype, Epigenomics, Castration resistant and Receptor in his study of Cancer research.
His Oncology study combines topics in areas such as MEDLINE, Enzalutamide, Carcinoma, Docetaxel and Prospective cohort study.
When carried out as part of a general Internal medicine research project, his work on Hematology and Outpatient clinic is frequently linked to work in Restructuring, therefore connecting diverse disciplines of study.
His study in Biopsy is interdisciplinary in nature, drawing from both Cancer, Prostate and Adenocarcinoma.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
